NeuClone Company Profile

A clinical-stage biopharmaceutical company focused on high quality, affordable biosimilars.

- NeuClone is developing 20 biosimilar antibody products for global commericalisation
- Vision to provide affordable life-saving and life-extending therapies, globally
- Vision made possible by *'Right from the Start®'* biosimilar approach, including the NeuMAX® platform and industry leading analytic capabilities
- Two biosimilars have completed Phase I clinical development
- Several additional biosimilars to be Phase I ready by 2021
- Lead biosimilar product referencing Stelara® targeting over $9b originator market with 'First to market' potential
- Large-scale, high quality strategic manufacturing partner secured
- Seeking partners for co-development and commercialization of biosimilar products

BIOSIMILAR PIPELINE

Originator	Product Category	Patent Expiry (EU/US)	2019 Sales (US$bn)
Stelara® (ustekinumab)	Autoimmune	2024/2023	$6.6b
Herceptin® (trastuzumab)	Breast cancer	2014/2019	$6.3b
Perjeta® (pertuzumab)	Breast cancer	2025/2025	$3.7b
Prolia/XGEVA® (denosumab)	Osteoporosis/ Oncology	2025/2025	$5.1b
Synagis® (palivizumab)	RSV prevention	2015/2015	$1.0b
Opdivo® (nivolumab)	Oncology	2030/2028	$8.0b
Keytruda® (pembrolizumab)	Oncology	2030/2028	$11.1b
Humira® (adalimumab)	Autoimmune	2018/2023	$19.7b
+12 additional products	-	-	-



KEY DIFFERENTIATORS

NeuClone's ***'Right from the Start'*** development approach enables efficient production of high quality biosimilars at low cost by incorporating the **NeuMAX®** technology platform and **industry leading analytic capabilities**.

NeuMAX® Technology Platform

1) NeuPRO™
Manufacturing process

2) NeuCHO®
Host cell line

3) NeuMAX™ Vectors
Custom expression vectors

Enables low cost manufacture of biologics



Industry Leading Analytic Capabilities

NeuClone conducts extensive in-house analytical testing from the earliest stages and throughout development to ensure a high level of biosimilarity for NeuClone's products.

Deep in-house capabilities include cell based assays, X-ray crystallography analysis, glycosylation, potency and more.



NeuClone's X-ray crystallography overlay of **Stelara® originator** & **NeuLara biosimilar**

NEUCLONE BIOSIMILAR ACTIVITIES

Biosimilar expression and upstream development → Analytical characterisation and biosimilarity confirmation → Clinical and non-clinical trials

STRATEGIC MANUFACTURING COLLABORATION

NeuClone and Serum Institute Collaboration

- Agreement initiated in 2014 to collaboratively develop 10 biosimilars
  - NeuClone is responsible for biosimilar development
  - Serum Institute is responsible for clinical supply and large-scale commercial manufacture
- NeuClone holds commercial rights to products in the US, Europe, Japan, Australia, New Zealand, South Korea and China. Serum Institute holds rights to the rest of the world
- Product supply to meet US FDA and EMA regulatory standards
- Large-scale manufacturing facility dedicated to NeuClone biosimilars
- Two biosimilars (trastuzumab & ustekinumab) developed through Phase I under the collaboration

About Serum Institute of India

- Largest manufacturer of vaccines globally by volume
  - over 1.5 billion doses annually across 50 vaccine products
  - exports to over 170 countries
  - 65% of the world's children receive a Serum Institute vaccine
- Aims to replicate its vaccine success with biosimilars through high-quality, affordable, large-scale production, for global supply
- Experienced in all steps of scale-up, manufacture and formulation, including commercial erythropoietin biosimilar and a fully human rabies monoclonal antibody
- Facilities in India and Netherlands (EU certified)
- Leader in the global response to COVID-19, both in development and mass production of multiple vaccine candidates, such as supplying over 1 billion vaccine doses developed by the University of Oxford & AstraZeneca

NEUCLONE ADVANTAGE: QUALITY, CAPACITY, COST

- NeuClone's expertise is in the most risk-intensive stages of biosimilar development (before Phase I completion)
- Through its unique platform technology and manufacturing partnership, NeuClone delivers low cost manufacturing at large capacity for global supply
- Additionally, NeuClone benefits from the Australian R&D Tax Incentive scheme to reduce development costs by up to 41%
- Lowest drug supply price globally allows for pricing flexibility and return on investment in price competitive markets

NEULARA (USTEKINUMAB)

NeuClone's Lead Biosimilar 'NeuLara' Referencing Stelara® (ustekinumab)

- Stelara® (ustekinumab) is approved for plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis
- Stelara® 2019 global sales were US$6.6 billion and expected to reach over US$ 9 billion prior to biosimilar entry in 2024
- NeuClone's ustekinumab biosimilar, designated as 'NeuLara', was the first ustekinumab biosimilar to enter clinical development in the Developed World
- NeuLara is completing a Phase I clinical trial. Safety results demonstrate no difference between NeuLara and Stelara-EU and Stelara-US. Pharmacokinetic (PK) results expected September 2020
- NeuLara is on track to be 'first to market' and capture a significant share of the >US$ 9 billion Stelara® market
- Global Phase III clinical trial planned for 2021

JOHN OKSINSKI | Head of Global Business Development and Alliances
PHONE: +612 9209 4020
EMAIL: j.oksinski@neuclone.com
WEBSITE: www.neuclone.com